Compare Figs Inc (FIGS) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Figs Inc vs Twist Bioscience Corp — how do they compare? Figs Inc trades at $15.17 (market cap $2.49B), while Twist Bioscience Corp trades at $159.89 (market cap $10.08B). The key difference: Twist Bioscience Corp is far larger — about 4× Figs Inc's market cap, and Figs Inc is more actively traded (5,964,311 versus 4,229,037). Which is the better fit depends on your goals — on Pluang, investors hold Figs Inc for 33 Days and Twist Bioscience Corp for 27 Days on average.
| FIGS | TWST | |
|---|---|---|
Market Cap | $2.49B | $10.08B |
Volume | 5,964,311 | 4,229,037 |
Sector | Consumer Cyclical | Health |
52-Week High | $17.12 | $205.00 |
52-Week Low | $6.90 | $25.45 |
Typical Hold Time | 33 Days | 27 Days |
Enterprise Value | $2.25B | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIGS trades at $14.06, down 0.28% on the day, with a bullish technical signal supported by moving averages. The company shows strong revenue growth with 2025 revenue reaching $631.10M and net income of $34.25M, representing a 5.42% margin. Recent earnings beats and raised 2026 guidance indicate positive momentum, though valuation ratios remain elevated with a P/E of 45.39 and P/S of 4.02.
Wall Street maintains a bullish stance with 60% buy ratings and a $18.00 consensus price target, suggesting 28% upside potential. Key risks include execution challenges in international expansion and rich valuation multiples that require continued strong performance. The company's expanding customer base and international growth provide catalysts for future appreciation.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
